Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER‑2‑positive breast cancer patients

Wu,Di; Xiong,Liangfa

doi:10.3892/ol.2020.11277

Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER‑2‑positive breast cancer patients

Authors:
- Di Wu
- Liangfa Xiong
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China
Published online on: January 24, 2020 https://doi.org/10.3892/ol.2020.11277
Pages: 2539-2546

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor‑2 (HER‑2)‑positive breast cancer patients was investigated. A total of 180 HER‑2‑positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α), cellular immune indexes of T‑lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), and the oxidative stress indexes superoxide dismutase (SOD) and myeloperoxidase (MPO) were observed before and after treatment and were compared between both groups. Patients were followed up for 5 years, and the 5‑year disease‑free survival (DFS), as well as the overall survival (OS) were compared. Clinical efficacy and pathological efficacy in the RG were significantly higher than those in the CG, and the incidence rate of adverse reactions had no significant difference between the two groups. There was no significant difference in inflammatory factors, cellular immune indexes and oxidative stress indexes between the two groups before treatment. After treatment, the levels of IL‑6, TNF‑α, CD8+ and MPO in both groups were significantly reduced and were significantly lower in RG than those in CG. However, the levels of CD4+, CD4+/CD8+ and SOD in both groups were significantly increased after treatment and were significantly higher in RG than those in CG. The 5‑year DFS and OS of the RG were significantly higher than those of the CG. In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5‑year DFS and OS in HER‑2‑positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress.

View Figures

View References

1	Asif HM, Sultana S, Ahmed S, Akhtar N and Tariq M: HER-2 positive breast cancer-a mini-review. Asian Pac J Cancer Prev. 17:1609–1615. 2016.PubMed/NCBI
2	Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E, Bjelic-Radisic V, et al European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and Breast Cancer Group; EORTC Headquarters, : Health-related quality of life in locally advanced and metastatic breast cancer: Methodological and clinical issues in randomised controlled trials. Lancet Oncol. 17:e294–e304. 2016.PubMed/NCBI
3	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017.PubMed/NCBI
4	Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, et al: Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci. 107:45–52. 2016.PubMed/NCBI
5	Luhtala S, Staff S, Tanner M and Isola J: Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. Tumour Biol. 37:9813–9823. 2016.PubMed/NCBI
6	Grosset AA, Poirier F, Gaboury L and St-Pierre Y: Galectin-7 expression potentiates her-2-positive phenotype in breast cancer. PLoS One. 11:e01667312016.PubMed/NCBI
7	Yang F, Lyu S, Dong S, Liu Y, Zhang X and Wang O: Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. OncoTargets Ther. 9:761–772. 2016.
8	Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al: Breast cancer version 2.2015. J Natl Compr Canc Netw. 13:448–475. 2015.PubMed/NCBI
9	Ahmed S, Sami A and Xiang J: HER2-directed therapy: Current treatment options for HER2-positive breast cancer. Breast Cancer. 22:101–116. 2015.PubMed/NCBI
10	Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and Bai XZ: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 6:11652–11663. 2015.PubMed/NCBI
11	Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H III, et al: Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol. 35:141–148. 2017.PubMed/NCBI
12	Hendricks WPD, Briones N, Halperin RF, Facista S, Heaton PR, Mahadevan D and Kim S: Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer. Cancers (Basel). 11:E15662019.PubMed/NCBI
13	Ho GY, Woodward N and Coward JI: Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 102:37–46. 2016.PubMed/NCBI
14	Theile D: Under-reported aspects of platinum drug pharmacology. Molecules. 22:3822017.
15	Denkert C, Loibl S, Salat C, Sinn BV, Schem C, Endris V, Klare P, Schmitt WD, Blohmer JU, Weichert W, et al: Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). Cancer Res. 73:(abstract nr S1-06). 2013.
16	Clarke SJ and Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 36:99–114. 1999.PubMed/NCBI
17	Lyseng-Williamson KA and Fenton C: Docetaxel: A review of its use in metastatic breast cancer. Drugs. 65:2513–2531. 2005.PubMed/NCBI
18	Leung HW, Chan AL, Muo CH and Leung JH: Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Rev Pharmacoecon Outcomes Res. 18:207–213. 2018.PubMed/NCBI
19	Echavarria I, Granja M, Bueno C, Lopez-Tarruella S, Peinado P, Sotelo M, Jerez Y, Moreno F, Torres G, Lobo M, et al: Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat. 162:181–189. 2017.PubMed/NCBI
20	Kataja V and Castiglione M; ESMO Guidelines Working Group, : Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20 (Suppl 4):10–14. 2009.PubMed/NCBI
21	Keil S, Barabasch A, Dirrichs T, Bruners P, Hansen NL, Bieling HB, Brümmendorf TH and Kuhl CK: Target lesion selection: An important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1. Invest Radiol. 49:509–517. 2014.PubMed/NCBI
22	Shintia C, Endang H and Diani K: Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol. 38:25–32. 2016.PubMed/NCBI
23	Hornbeck PV: Enzyme-linked immunosorbent assays. Curr Protoc Immunol. 110:2.1.1–23. 2015.
24	Cho YA, Sung MK, Yeon JY, Ro J and Kim J: Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res Treat. 45:210–219. 2013.PubMed/NCBI
25	Thriveni K, Raju A, Ramaswamy G, Shachidevi Krishnamurthy S and Kumar R: Tumor necrosis factor: An inflammatory microenvironment marker in primary breast cancer patients. IJMIO. 3:252018.
26	Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, Siddiqui-Jain A, O'Brien S, Padgett C, Lim JK, et al: Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun. 415:163–167. 2011.PubMed/NCBI
27	Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, et al: Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen. Breast J. 13:337–345. 2007.PubMed/NCBI
28	Tripsianis G, Papadopoulou E, Anagnostopoulos K, Botaitis S, Katotomichelakis M, Romanidis K, Kontomanolis E, Tentes I and Kortsaris A: Coexpression of IL-6 and TNF-α: Prognostic significance on breast cancer outcome. Neoplasma. 61:205–212. 2014.PubMed/NCBI
29	Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH and Park SY: Tumour-infiltrating CD8⁺ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 109:2705–2713. 2013.PubMed/NCBI
30	Wang B and Pan F: Analysis of T lymphocyte subsets in peripheral blood of patients with breast cancer and its clinical value. Int J Lab Med. 39:1230–1232, 1237. 2018.
31	Sahu A, Varma M and Kachhawa K: A prognostic study of MDA, SOD and catalase in breast Cancer patients. Int J Sci Res (Ahmedabad). 4:157–159. 2015.
32	Fernandes AS, Saraiva N and Oliveira NG: Redox therapeutics in breast cancer: Role of SOD mimics. Redox-Active Therapeutics. Batinic-Haberle I, Reboucas JS and Spasojevic I: Springer. (Cham, Switzerland). 451–467. 2016.
33	Yang WJ, Wang MY, Pan FZ, Shi C and Cen H: Association between MPO-463G>A polymorphism and cancer risk: Evidence from 60 case-control studies. World J Surg Oncol. 15:1442017.PubMed/NCBI
34	Abusoglu S, Eryavuz D, Bal C, Nural C, Ozcan E, Yildirimel M, Celik S and Unlu A: Assessment of serum ischemia-modified albumin, prolidase and thiol-disulphide levels in subjects with breast cancer. Rev Rom Med Lab. 27:25–33. 2019.
35	Zapf I, Moezzi M, Fekecs T, Nedvig K, Lőrinczy D and Ferencz A: Influence of oxidative injury and monitoring of blood plasma by DSC on breast cancer patients. J Therm Anal Calorim. 123:2029–2035. 2016.